These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

124 related articles for article (PubMed ID: 23507609)

  • 1. [Chronic myeloid leukemia maintained major molecular response with intermittent dosage of imatinib mesylate].
    Miyashita K; Fujimaki K; Ishigatsubo Y
    Gan To Kagaku Ryoho; 2013 Mar; 40(3):405-7. PubMed ID: 23507609
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The significance of myelosuppression during therapy with imatinib mesylate in patients with chronic myelogenous leukemia in chronic phase.
    Sneed TB; Kantarjian HM; Talpaz M; O'Brien S; Rios MB; Bekele BN; Zhou X; Resta D; Wierda W; Faderl S; Giles F; Cortes JE
    Cancer; 2004 Jan; 100(1):116-21. PubMed ID: 14692031
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Durable responses in chronic myeloid leukemia patients maintained with lower doses of imatinib mesylate after achieving molecular remission.
    Carella AM; Lerma E
    Ann Hematol; 2007 Oct; 86(10):749-52. PubMed ID: 17576558
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparison between patients with Philadelphia-positive chronic phase chronic myeloid leukemia who obtained a complete cytogenetic response within 1 year of imatinib therapy and those who achieved such a response after 12 months of treatment.
    Iacobucci I; Rosti G; Amabile M; Poerio A; Soverini S; Cilloni D; Testoni N; Abruzzese E; Montefusco E; Ottaviani E; Iuliano F; Russo D; Gobbi M; Alimena G; Martino B; Terragna C; Pane F; Saglio G; Baccarani M; Martinelli G
    J Clin Oncol; 2006 Jan; 24(3):454-9. PubMed ID: 16421422
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Imatinib mesylate in Philadelphia chromosome-positive, chronic-phase myeloid leukemia after failure of interferon alpha.
    Tóthová E; Kafková A; Fricová M; Benová B; Kirschnerová G; Tóthová A
    Neoplasma; 2005; 52(1):63-7. PubMed ID: 15739029
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Imatinib mesylate discontinuation in patients with chronic myeloid leukemia who have received front-line imatinib mesylate therapy and achieved complete molecular response.
    Yhim HY; Lee NR; Song EK; Yim CY; Jeon SY; Shin S; Kim JA; Kim HS; Cho EH; Kwak JY
    Leuk Res; 2012 Jun; 36(6):689-93. PubMed ID: 22398220
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Hematological and molecular response evaluation of CML patients on imatinib.
    Gupta A; Prasad K
    J Assoc Physicians India; 2007 Feb; 55():109-13. PubMed ID: 17571739
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Phase IV study evaluating efficacy of escalated dose of imatinib in chronic myeloid leukemia patients showing suboptimal response to standard dose imatinib.
    Koh Y; Kim I; Yoon SS; Kim BK; Kim DY; Lee JH; Lee KH; Park E; Kim HJ; Sohn SK; Joo YD; Kim SJ; Chung J; Shin HJ; Kim SH; Kim CS; Song HS; Kim MK; Hyun MS; Ahn JS; Jung CW; Park S;
    Ann Hematol; 2010 Jul; 89(7):725-31. PubMed ID: 20179930
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Molecular responses in patients with chronic myelogenous leukemia in chronic phase treated with imatinib mesylate.
    Cortes J; Talpaz M; O'Brien S; Jones D; Luthra R; Shan J; Giles F; Faderl S; Verstovsek S; Garcia-Manero G; Rios MB; Kantarjian H
    Clin Cancer Res; 2005 May; 11(9):3425-32. PubMed ID: 15867244
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Is it possible to discontinue imatinib mesylate therapy in Chronic Myeloid Leukemia patients with undetectable BCR/ABL? A case report and a review of the literature.
    Guastafierro S; Falcone U; Celentano M; Coppola M; Ferrara MG; Sica A
    Leuk Res; 2009 Aug; 33(8):1079-81. PubMed ID: 19167064
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Efficacy of imatinib mesylate, a specific inhibitor of BCR/ABL tyrosine kinase, on chronic myeloid leukemia in blast phase].
    Zhang GC; Zheng D; Li QH; Li XH; Cai CC; Luo SK; Li J; Peng AH; Tong XZ; Tan EX; Hong WD
    Ai Zheng; 2004 Dec; 23(12):1696-9. PubMed ID: 15601563
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Approval summary for imatinib mesylate capsules in the treatment of chronic myelogenous leukemia.
    Cohen MH; Williams G; Johnson JR; Duan J; Gobburu J; Rahman A; Benson K; Leighton J; Kim SK; Wood R; Rothmann M; Chen G; U KM; Staten AM; Pazdur R
    Clin Cancer Res; 2002 May; 8(5):935-42. PubMed ID: 12006504
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Imatinib Mesylate Dose Adjustment Based on Body Surface Area for CML Chronic Phase Patients Intolerant to Standard Dosage.
    Sung HJ; Lee SR; Choi IK; Park Y; Choi CW; Kim HJ; Yhim HY; Kim BS
    Acta Haematol; 2015; 134(1):59-68. PubMed ID: 25871321
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Sustained complete molecular remission after cessation of imatinib mesylate treatment in a patient with relapsed chronic myelogenous leukemia after allogeneic stem cell transplantation].
    Igarashi T; Hayashi T; Yasui H; Ikeda H; Takahashi T; Ishida T; Shinomura Y
    Rinsho Ketsueki; 2012 Feb; 53(2):215-8. PubMed ID: 22450581
    [TBL] [Abstract][Full Text] [Related]  

  • 15. No significance of derivative chromosome 9 deletion on the clearance kinetics of BCR/ABL fusion transcripts, cytogenetic or molecular response, loss of response, or treatment failure to imatinib mesylate therapy for chronic myeloid leukemia.
    Kim DH; Popradi G; Sriharsha L; Kamel-Reid S; Chang H; Messner HA; Lipton JH
    Cancer; 2008 Aug; 113(4):772-81. PubMed ID: 18543309
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Imatinib mesylate in chronic myeloid leukemia: a prospective, single arm, non-randomized study.
    Deshmukh C; Saikia T; Bakshi A; Amare-Kadam P; Baisane C; Parikh P
    J Assoc Physicians India; 2005 Apr; 53():291-5. PubMed ID: 15987013
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Sustained cytogenetic response after discontinuation of imatinib mesylate in a patient with chronic myeloid leukaemia.
    Ghanima W; Kahrs J; Dahl TG; Tjonnfjord GE
    Eur J Haematol; 2004 Jun; 72(6):441-3. PubMed ID: 15128424
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia.
    Druker BJ; Guilhot F; O'Brien SG; Gathmann I; Kantarjian H; Gattermann N; Deininger MW; Silver RT; Goldman JM; Stone RM; Cervantes F; Hochhaus A; Powell BL; Gabrilove JL; Rousselot P; Reiffers J; Cornelissen JJ; Hughes T; Agis H; Fischer T; Verhoef G; Shepherd J; Saglio G; Gratwohl A; Nielsen JL; Radich JP; Simonsson B; Taylor K; Baccarani M; So C; Letvak L; Larson RA;
    N Engl J Med; 2006 Dec; 355(23):2408-17. PubMed ID: 17151364
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Acute myeloid leukemia developing during imatinib mesylate therapy for chronic myeloid leukemia in the absence of new cytogenetic abnormalities.
    Pawarode A; Sait SN; Nganga A; Coignet LJ; Barcos M; Baer MR
    Leuk Res; 2007 Nov; 31(11):1589-92. PubMed ID: 17391756
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical characteristics and hematologic responses to Imatinib in patients with chronic phase myeloid leukemia (CML) at Cipto Mangunkusumo Hospital.
    Reksodiputro AH; Syafei S; Prayogo N; Karsono B; Rinaldi I; Rajabto W; Mulansari NA
    Acta Med Indones; 2010 Jan; 42(1):2-5. PubMed ID: 20305324
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.